Zinzani, P. L. Et Al. 2021. CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL). EHA 2021 .

Zinzani, P. L., Capra, M., ÖZCAN, M., Lv, F., Li, W., Yañez, E., ... Sapunarova, K.(2021). CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL) . EHA 2021

Zinzani, Pier Et Al. "CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)," EHA 2021, 2021

Zinzani, Pier L. Et Al. "CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)." EHA 2021 , 2021

Zinzani, P. L. Et Al. (2021) . "CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)." EHA 2021 .

@conferencepaper{conferencepaper, author={Pier Luigi Zinzani Et Al. }, title={CHRONOS-3: randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL)}, congress name={EHA 2021}, city={}, country={}, year={2021}}